Aptar Reports First Quarter 2024 Results
Aptar Declares Quarterly Dividend
Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced that the recent approval by the National Medical Products Administration (NMPA) in China of Sinomune Pharmaceutical’s Li Fu metronidazole gel for the treatment of papulopustular rosacea uses Aptar Pharma’s Mezzo+ CS (China Support) Airless dispensing solution for dermal drug delivery.
Aptar Pharma Continues Global Expansion with North America Capacity Extension
Aptar Named One of Barron’s 100 Most Sustainable U.S. Companies
Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions
Aptar Reports Fourth Quarter and Annual 2023 Results
Aptar Declares Quarterly Dividend and Announces 2024 Annual Meeting Details
Aptar to Present at 42nd Annual J.P. Morgan Healthcare Conference
Aptar Announces 2024 Quarterly Conference Call Dates